Upstream Bio: Maintaining Buy Rating On Verekitug Success In Phase 2 CRSwNP Study [Seeking Alpha]
Upstream Bio, Inc. (UPB)
Company Research
Source: Seeking Alpha
Verekitug's once-every-12-weeks dosing offers competitive differentiation versus standard of care and existing biologics like Tezspire. Upcoming UPB catalysts includes phase 2 VALIANT data in severe asthma expected in Q1 of 2026. UPB maintains a strong cash runway through 2027, minimizing dilution risk and supporting continued pipeline advancement. AnnaStills/iStock via Getty Images The last time I spoke about Upstream Bio, Inc. UPB ) it was in a Seeking Alpha article entitled "Upstream Bio: Treating Respiratory Disorders With TSLP Targeting Differentiation." With respect to this article, I noted that the More on my IG service This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutic
Show less
Read more
Impact Snapshot
Event Time:
UPB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
UPB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
UPB alerts
High impacting Upstream Bio, Inc. news events
Weekly update
A roundup of the hottest topics
UPB
News
- Upstream Bio (NASDAQ:UPB) is now covered by analysts at Lifesci Capital. They set an "outperform" rating and a $43.00 price target on the stock.MarketBeat
- Upstream Bio (UPB): Evaluating Valuation After 10% Share Price Surge [Yahoo! Finance]Yahoo! Finance
- Upstream Bio to Participate in Upcoming December Investor Conferences [Yahoo! Finance]Yahoo! Finance
- Upstream Bio to Participate in Upcoming December Investor ConferencesGlobeNewswire
- Upstream Bio Reports Third Quarter 2025 Financial Results and Highlights Continued ProgressGlobeNewswire
UPB
Sec Filings
- 11/14/25 - Form SCHEDULE
- 11/14/25 - Form SCHEDULE
- 11/5/25 - Form S-3ASR
- UPB's page on the SEC website